This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.
ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as SOLIQUA®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.
American Diabetes Association. Diabetes Care 2023;46(Suppl. 1):S140–S157 | https://doi.org/10.2337/dc23-S009
MAT-BH-2300161/v1/March 2023
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.